PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
PMV Pharmaceuticals (NASDAQ: PMVP) achieved significant milestones, including FDA clearance for its investigational new drug PC14586, aimed at treating solid tumors with the p53 Y220C mutation. The company raised approximately $243.5 million through its IPO, optimizing its capital to further clinical development and expand its discovery pipeline. PMVP reported third-quarter results with $373.1 million in cash, a net loss of $8.8 million, and a rise in R&D and G&A expenses compared to the previous year. Fast Track designation from the FDA also enhances the development pace of PC14586.
PMV Pharmaceuticals announced that the FDA has granted Fast Track designation to its lead candidate, PC14586, aimed at treating cancer patients with a specific p53 Y220C mutation. This designation highlights the potential of PC14586 to meet a critical medical need, as there are no current FDA-approved therapies targeting this mutation found in various cancers. The planned Phase 1/2 studies will assess the drug's safety and efficacy in patients with locally advanced or metastatic solid tumors. Overall, this development could significantly enhance treatment options for patients facing poor outcomes due to p53 mutations.
PMV Pharmaceuticals has successfully closed its initial public offering, selling 13,529,750 shares of common stock at a price of $18.00 per share, generating approximately $243.5 million in gross proceeds. The offering included 1,764,750 additional shares exercised by underwriters. PMV Pharma focuses on small molecule therapies targeting p53 mutations, which are prevalent in nearly 50% of all cancers. The company is listed on the Nasdaq under the ticker symbol 'PMVP' and aims to leverage funds for further development in precision oncology.
PMV Pharmaceuticals, Inc. has successfully closed its initial public offering, selling 13,529,750 shares at $18.00 each, raising approximately $243.5 million in gross proceeds. The offering included the underwriters' full exercise of their option to purchase an additional 1,764,750 shares. The offering was registered with the SEC, effective September 24, 2020, and all shares were offered by PMV Pharma. Goldman Sachs, BofA Securities, Cowen, and Evercore ISI acted as joint book-running managers for this offering. PMV Pharma focuses on developing therapies targeting p53 mutations found in many cancers.
PMV Pharmaceuticals has announced the pricing of its initial public offering (IPO) of 11,765,000 shares at $18.00 per share, aiming to raise approximately $211.8 million before expenses. The IPO is set to begin trading on the Nasdaq under the ticker symbol PMVP on September 25, 2020, with the offering expected to close on September 29, 2020. The underwriters have a 30-day option to purchase an additional 1,764,750 shares at the IPO price. Key financial firms are managing the offering, and a registration statement has been filed with the SEC.